Amy Peterson has joined CytomX Therapeutics (NASDAQ: [[ticker:CTMX]]) as executive vice president and chief development officer. Peterson was most recently chief medical officer of immune-oncology at BeiGene (NASDAQ: [[ticker:BGNE]]). Her experience also includes positions at Medivation and Roche subsidiary Genentech. South San Francisco-based CytomX is developing antibody drugs that treat cancer.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
